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In spite of the current optimal therapy, the mortality of patients with ischemic heart disease (IHD) remains high,
particularly in cases with diabetes mellitus (DM) as a co-morbidity. Myocardial infarct size is a major determinant of
prognosis in IHD patients, and development of a novel strategy to limit infarction is of great clinical importance.
Ischemic preconditioning (PC), postconditioning (PostC) and their mimetic agents have been shown to reduce
infarct size in experiments using healthy animals. However, a variety of pharmacological agents have failed to
demonstrate infarct size limitation in clinical trials. One of the possible reasons for the discrepancy between the
results of animal experiments and clinical trials is that co-morbidities, including DM, modified myocardial responses
to ischemia/reperfusion and to cardioprotective agents. Here we summarize observations of the effects of DM on
myocardial infarct size and ischemic PC and PostC and discuss perspectives for protection of DM hearts.
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Cardiovascular diseases are the leading cause of death,
accounting for approximately 30% of all deaths world-
wide [1]. Among the various cardiovascular diseases,
acute myocardial infarction (AMI) has a high rate of
mortality, and infarct size is a primary determinant of
prognosis in these patients. The only established and
clinically approved method to limit infarct size is restor-
ation of coronary blood flow by percutaneous coronary
interventions (PCI), thrombolytic agents or coronary by-
pass surgery. However, our recent review of clinical in-
farct size data indicated that infarct size after current
reperfusion therapy was larger than 75% of the area at
risk and larger than 20% of the left ventricle in one
fourth of AMI patients [2]. Lack of substantial myocar-
dial salvage in those patients cannot be simply at-
tributable to long symptom-to-reperfusion time, and
involvement of reperfusion injury [3] is also possible.
Nevertheless, significant percentages of AMI patients
suffer from insufficient cardiac function and have a poor* Correspondence: tmiki@sapmed.ac.jp
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reproduction in any medium, provided the orprognosis even after successful restoration of coronary
flow [2]. Therefore, the establishment of a novel strategy
to limit the extent of infarction during ischemia/reperfu-
sion is of great clinical importance.
As a cardioprotective strategy, ischemic precondition-
ing (PC) has received much attention for its potent in-
farct size-limiting effect since its first report by Murry
et al. in 1986 [4]. Zhao et al. found that “conditioning”
with repetitive ischemia/reperfusion at the time of
reperfusion also affords protection and named the
phenomenon ischemic postconditioning (PostC) [5]. La-
boratory investigations to date have clarified outlines of
the intracellular mechanisms of PC and PostC [6-9]. In
addition, several agents targeting signaling relevant to
PC and PostC have been shown to act as PostC
mimetics [6-8]. However, clinical benefits of PC, PostC
and their mimetics were not always demonstrated in
clinical trials [8,10]. The discrepancy between results of
animal studies and clinical trials may be explained by
notable differences between animal models of AMI and
AMI in humans [2,10]. First, there are species differ-
ences in regulatory mechanisms of cardiomyocytes such
as contribution of sarcolemmal Ca2+ ATPase to overall
Ca2+ handling. Second, the timing of administration of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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animal studies and negative clinical trials. Third, most
of the patients with AMI were pretreated with pharma-
cological agents for their co-morbidities at the onset of
AMI, whereas animals were untreated, except for
anesthetic agents, before AMI in most of the previous
studies. Pharmacological agents used for treatment of
hypertension, dyslipidemia and/or diabetes mellitus
(DM) potentially modify intracellular signaling relevant
to cytoprotection and thus myocardial responses to PC,
Post and PC mimetics. Fourth, AMI patients recruited
to clinical studies were generally old and had concomi-
tant diseases, whereas relatively young and healthy ani-
mals were used in most of the previous animal studies.
Aging and co-morbidities have been shown to modify
or even abrogate the infarct size-limiting effects of
interventions in animal experiments [6,11] and thus
possibly underlie the negative results in clinical trials.
Of morbidities that potentially compromise the pro-
tective mechanisms of the heart, DM appears primarily
important to study today. The number of patients with
DM has been increasing worldwide in the past two
decades, and these patients are predisposed to serious
cardiovascular morbidity and mortality [12]. Despite re-
cent progress in coronary intervention strategies, DM is
associated with higher mortality after AMI due to more
extensive atherosclerotic lesions and also hypertrophied
and dysfunctional left ventricle [13-15]. Interestingly,
Lamblin et al. recently showed that rates of cardiovas-
cular death and heart failure after the first AMI were
higher in DM patients than in non-DM patients,
though ventricular function and remodeling were com-
parable in the two groups [16]. The increased mortality
after AMI in DM patients is unlikely to be prevented
simply by improvement of glycemic control, since in-
tensive glycemic controls failed to reduce cardiovascu-
lar events as well as mortality rate in DM patients in
recent large-scale clinical trials [17-19]. Hence, we need
novel strategies for protecting DM patients with coron-
ary artery diseases from excessive myocardial ischemia-
reperfusion injury. To gain an insight into a novel
strategy, we thoroughly review reported effects of DM on
myocardial infarct size and on protective mechanisms
against infarction and discuss future perspectives in this
article. Our discussion on pathophysiology and clinical
approach to diabetic cardiomyopathy was recently pub-
lished elsewhere [20].Changes in myocardial susceptibility to infarction
by DM
Clinical studies showed that DM increased the suscepti-
bility of the myocardium to ischemia/reperfusion injury
[21,22]. However, results of infarct size studies indiabetic animal models were contradictory (Tables 1 and
2), and the reason for the inconsistency remains unclear.
Multiple mechanisms are involved in cardiomyocyte
necrosis induced by ischemia/reperfusion. Depletion of
intracellular ATP, intracellular overloading with Na+ and
Ca2+, and increased fragility of the cell membrane are
major changes during ischemia relevant to cell necrosis.
Accumulating evidence supports the notion that the
mitochondrial permeability transition pore (mPTP) is
primed during ischemia and is opened by Ca2+ overload
and burst of reactive oxygen species at the time of reper-
fusion, leading to irreversible loss of mitochondrial func-
tions and cell necrosis [23]. Theoretically, modification of
ischemia-induced changes or reperfusion-induced open-
ing of the mPTP should underlie the change in myocar-
dial susceptibility to infarction in DM hearts. However,
such modification has not been understood well.
Experimental studies
Infarct size in animal models of DM was larger or smal-
ler than or similar to, depending on reports, that in non-
diabetic controls (Table 1). As shown in Table 1, there
were numerous differences in experimental preparations
and protocols, and a single factor cannot entirely explain
the discrepancy in the effects of DM on infarct size.
Duration of the diabetic state and plasma level of insulin
(i.e., type 1 DM vs. type 2 DM) appear to influence myo-
cardial tolerance against infarction. In a study by Ravin-
gerová et al. [24], infarct size after 30-min ischemia was
smaller in diabetic rat hearts at 1 week after streptozoto-
cin (STZ) injection than in controls, but this infarct size
limitation was not detected 8 weeks later. Two other
studies have also shown that resistance of diabetic hearts
to ischemia/reperfusion injury was detectable at the
early phase of DM and disappeared later [25,26]. How-
ever, enlargement of infarct size was observed as early as
8 days after STZ injection [27-29], indicating that dur-
ation of DM is not the only factor responsible for incon-
sistent effects of DM on infarct size.
Difference in metabolic profiles associated with DM
(i.e., presence or absence of hyperinsulinemia and types
of dyslipidemia) may also be responsible for different
changes in infarct size in DM animals. With a few
exceptions [30,31], DM models with obesity and hyper-
insulinemia showed increased myocardial susceptibility
to ischemia/reperfusion-induced necrosis [32-41]. In
contrast, high glucose level induced simply by glucose
or dextrose infusion did not affect infarct size in the
majority of studies, including two recent studies [42,43]
(Table 2).
Clinical studies
Increased myocardial susceptibility to infarction in DM
patients was indicated by two clinical studies: infarct size
Table 1 Effect of diabetes mellitus on infarct size
Species DM Index ischemia First author Journal
type duration min type
Infarct size enlargement
Dog 2 75 d 120 regional, vivo Forrat Cardiovasc Res 1993
Rat (SD) 1 8 d 25 regional, vivo Marfella Diabetologia 2002
Rat (SD) 1 8 d 25 regional, vivo Di Filippo Diabetes 2005
Rat (SD) 1 30 d 30 global, vitro Thirunavukkarasu Free Radic Biol Med 2007
Rat (Wistar) 1 2 w 30 regional, vivo Xiao J Pharmacol Exp Ther 2004
Rat (Zucker obese) 2 30 regional, vivo Jordan J Pharmacol Exp Ther 2003
Rat (Zucker obese) 2 (10-12 w old) 30 regional, vivo Katakam Am J Physiol 2007
Rat (Zucker diabetic fatty) 2 (10-12 w old) 30 regional, vivo Yue Diabetes 2005
Rat (Zucker diabetic fatty) 2 (12-16 w old) 30 regional, vivo La Bonte Am J Physiol 2008
Rat (OLETF) 2 (25-30 w old) 20 regional, vivo Miki Diabetes 2009
Rat (OLETF) 2 (25-30 w old) 20 regional, vivo Hotta Circ Res 2010
Mice 1 8 d 25 regional, vivo Marfella Diabetes 2004
Mice 1 4 w 60 regional, vivo Liu Diabetes 2005
Mice (ob/ob) 2 (8-10 w old) 30 regional, vivo Bouhidel Am J Physiol 2008
Mice (ob/ob) 2 (8-10 w old) 30 regional, vivo Calvert Diabetes 2008
Mice (ob/ob) 2 (10-12 w old) 30 regional, vivo Zhu J Cell Mol Med 2011
Mice (KK-Ay) 2 (6 w old) 40 regional, vivo Honda J Mol Cell Cardiol 2008
Infarct size reduction
Rabbit (NZ) 1 8 w 30 regional, vivo Hadour J Mol Cell Cardiol 1998
Rat (SD) 1 2 w 30 regional, vivo Ma N-S Arch Pharmacol 2006
Rat (Wistar) 2 11-12 m 30, 45 regional, vivo Liu Circulation 1993
Rat (Wistar) 1 1 w 30 regional, vivo Ravingerová Mol Cell Biochem 2003
Rat (Wistar) 1 4 w 30 regional, vivo Xu Exp Mol Pathol 2004
Rat (Wistar) 1 6 w 30 regional, vivo Galagudza Neurosci Behav Physiol 2007
Rat (Wistar) 2 10-12 w 30 global, vitro Kravchuk Exp Diabetes Res 2011
Rat (Wistar-Kyoto) 2 9 m 40 regional, vitro Mozaffari Hypertension 2003
Rat (Zucker diabetic fatty) 2 (16 w old) 50 regional, vitro Kristiansen Diabetologia 2004
Rat (Goto-Kakizaki) 2 (16 w old) 50 regional, vitro Kristiansen Diabetologia 2004
Rat (Goto-Kakizaki) 2 (16 w old) 45 regional, vitro Kristiansen Diabetologia 2011
No change in infarct size
Dog 1 3 w 60 regional, vivo Kersten Am J Physiol 2000
Dog 1 3 w 60 regional, vivo Kersten Am J Physiol 2001
Rabbit (NZ) 1 10-16 w 30 regional, vivo Vogel Circ Res 1988
Rabbit (NZ) 1 4-5 w 60 regional, vivo Nieszner Exp Clin Endocrinol Diabetes 2002
Rabbit (NZ white) 1 5-6 w 30 regional, vivo Ebel Pflügers Arch 2003
Rat (SD) 1 6 w 30 regional, vivo Ma N-S Arch Pharmacol 2006
Rat (SD) 1 2 w 30 regional, vivo Gross Diabetes 2007
Rat (SD) 1 4 w, 8 w 30 global, vitro Shi-Ting Biomed Pharmacother 2010
Rat (SD) 1 4-5 w 30 regional, vivo Drenger Anesthesiology 2011
Rat (SD) 1 4 w 30 global, vitro Okazaki J Mol Cell Cardiol 2011
Rat (Wistar) 1 8 w 30 regional, vitro Joyeux Cardiovasc Res 1999
Rat (Wistar) 1 8 w 30 regional, vivo Ravingerová Mol Cell Biochem 2003
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Table 1 Effect of diabetes mellitus on infarct size (Continued)
Rat (Wistar) 1 20 w 30 regional, vivo Xu Exp Mol Pathol 2004
Rat (Wistar) 1 4 w 25 global, vitro Ghaboura Basic Res Cardiol 2011
Rat (Goto-Kakizaki) 2 35 regional, vitro Tsang Diabetes 2005
Rat (Goto-Kakizaki) 2 35 regional, vitro Bhamra Basic Res Cardiol 2008
Rat (Goto-Kakizaki) 2 (12 w old) 35 regional, vivo Bulhak Am J Physiol 2009
Rat (Goto-Kakizaki) 2 30 regional, vivo Matsumoto Cardiovasc Drug Ther 2009
Mice 1 2 w 30 global, vitro Przyklenk Antioxid Redox Signal 2011
Mice (ob/ob) 2 (12-14 w old) 30 global, vitro Przyklenk Antioxid Redox Signal 2011
SD, Sprague–Dawley; NZ, New Zealand; OLETF, Otsuka Long-Evans-Tokushima fatty; d, days; w, weeks.
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was larger by 30 ~ 70% in DM patients than in non-DM
patients [21,22]. The change in myocardial tolerance to
infarction is consistent with worse short- and long-term
prognosis after AMI in DM patients [44,45]. Of particu-
lar relevance, Haffner et al. [46] showed that cardiovas-
cular event risk in DM patients without prior
myocardial infarction was comparable to the risk in









Dog before I 585 vs. 71 60
Rabbit (NZ white) throughout 594 vs. 99 30
Rat (SD) during I 324 vs 85 30
No change in infarct size
Dog before I 310 vs. 71 60
Dog before I 310 vs. 75 60
Dog before I 316, 579 vs. 78 60
Dog before I 307 vs 83 60
Rabbit (NZ white) before and during I 660 vs. 185 30
Rabbit (NZ white) before I 257 vs 124 30
Rabbit (NZ white) before and during I 338 vs 142 40
Rat (SD) before and during I 360 vs 112 30
Rat (Wistar) before and during I >400 vs. 121 25
Rat (Wistar) before and during I 459 vs 128 25
Rat (Wistar) before and during I 355 vs 89 30
Metabolic syndrome
Infarct size enlargement
Rat (Wistar) Western diet for 16 w 95 vs 87 40
No change in infarct size
Rat (SD) high fat diet for 13 w 160 vs 144 45
Rat (WOKW) (28 w old) 105 vs. ? 30
NZ New Zealand, SD Sprague–Dawley, WOKW Wistar-Ottawa-Karlsburg W, before I bHowever, the untoward effects of DM on prognosis after
AMI cannot be explained solely by increased myocardial
vulnerability to ischemia/reperfusion injury, since the
risk of heart failure and death was significantly higher in
DM patients than in non-DM patients with comparable
infarct sizes and left ventricular ejection fractions [47].
Myopathic changes (“diabetic cardiomyopathy”), im-
paired collateral recruitment, microcirculatory abnor-




regional, vivo Kersten Am J Physiol 1998
regional, vitro Wong J Diabetes Complications 2011
regional, vivo Su Am J Physiol 2007
regional, vivo Kersten Am J Physiol 1998
regional, vivo Kersten Am J Physiol 2001
regional, vivo Kehl Anesthesiology 2002
regional, vivo Gu Anesthesiology 2008
regional, vivo Ebel Pflugers Arch 2003
regional, vivo Amour Anesthesiology 2010
regional, vivo Raphael J Cardiovasc Pharmacol 2010
regional, vivo Ichinomiya Cardiovasc Diabetol 2012
regional, vivo Weber Eur J Pharmacol 2008
regional, vivo Huhn Br J Anaesth 2008
regional, vivo Matsumoto Cardiovasc Diabetol 2012
regional, vitro du Toit Am J Physiol 2008
regional, vivo Thim Clin Sci (Lond) 2006
regional, vivo Wagner J Cardiovasc Pharmacol 2008
efore ischemia, during I during ischemia, w weeks.
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bility to infarction, for detrimental prognosis after AMI
in DM patients.
Defects in intracellular protective signaling in DM
hearts
DM is one of the co-morbidities that potentially mod-
ify myocardial response to protective interventions, in-
cluding PC and PostC. A number of studies have been
carried out to determine the efficacy of ischemic PC
and PostC for protecting the myocardium in animal
models of DM (Tables 3 and 4) and diabetic patients
(Table 5). The majority of those studies showed that
DM interferes with protective mechanisms of cardio-
protective interventions. Myocardial protection by PC
and PostC is achieved by activation of multiple pro-
tective signaling pathways that appear to converge to
inhibit mPTP opening upon reperfusion via phosphor-
ylation of glycogen synthase kinase-3β (GSK-3β) at
Ser9 [6,8,9], and DM-induced defects in the protective
signaling may be different depending on the model
and/or phase of DM.
Experimental studies
With a few exceptions, previous studies demonstrated
that cardioprotection achieved by ischemic PC or PostC
is impaired in DM: the infarct size-limiting effect was
lost or required extra cycles of ischemia/reperfusion in
experimental diabetes (Table 3). Tsang et al. [48]
reported that one, two and three cycles of ischemic PC
significantly reduced infarct size in normal rats; however,
three cycles of ischemic PC were required to limit in-
farct size in diabetic Goto-Kakizaki rats. Their findings
suggested that the threshold for PC protection is
increased in the diabetic myocardium. Liu et al. [49]
were the first to examine the effects of DM on PC and
they reported preservation of PC protection in STZ-
induced DM. However, since they used a PC protocol
with multiple cycles of ischemia/reperfusion only, the
change in the threshold for inducing PC protection
might have been missed in their study. In fact, impair-
ment of PC by DM has been observed in multiple spe-
cies (rats, rabbits and dogs) and different models of DM
(STZ-induced type 1 DM and genetic models of type 2
DM) [30,37,50-54]. Mimetics of ischemic PC and PostC
(diazoxide, erythropoietin, [D-Ala2, D-Leu5]-enkephalin
acetate [DADLE] and isoflurane) were also ineffective
for limitation of infarct size in DM hearts [33,34,37,55-
59], confirming that DM impairs intracellular signaling
mechanisms relevant to myocardial protection.
Several steps in cytoprotective signaling have been
found to be disrupted by DM in the heart. Blocked or
attenuated signaling via phosphoinsitide-3 kinase
(PI3K)-Akt, extracellular signal-regulated kinase (ERK)and/or signal transducer and activator of transcription-3
(STAT3) pathways was detected in association with loss
or reduced efficiency of PC in protection against infarc-
tion [31,33,34,36,48,57-59]. Our recent studies have
shown that phosphorylation of Jak2, being upstream of
PI3K-Akt signaling, is inhibited by enhanced calcineurin
activity and that phosphorylation of GSK-3β by ERK is
lost by an endoplasmic reticulum stress-dependent
mechanism in OLETF, a rat model of obese type 2 DM
[33,34]. Furthermore, protein level of active GSK-3β, a
pro-necrotic and pro-apoptotic kinase, was increased in
mitochondria, leading to reduction in the threshold for
mPTP opening in response to Ca2+ overload [34]. On
the other hand, a protective mechanism downstream of
GSK-3β phosphorylation appears to be intact in diabetic
hearts, since direct pharmacological inhibitors of GSK-
3β limited infarct size in diabetic hearts as in non-
diabetic animals [33,34,54,57,58].
An important and clinically relevant issue is whether
hyperglycemia per se is responsible for disruption of
protective signaling in PC and PostC. Acute hypergly-
cemia induced by dextrose infusion attenuated infarct
size limitation by ischemic PC, a mitochondrial ATP-
sensitive K+ channel (KATP channel) opener and
anesthetic agents (Table 4). These results indicate a pri-
mary role of hyperglycemia in impairment of protective
signaling. Interestingly, Przyklenk et al. [31] reported
that the cardioprotective effect of ischemic PostC was
re-established in STZ-induced diabetic mice by pancreas
islet cell transplantation. Transplantation of islet cells in
diabetic mice normalized both blood glucose level and
free fatty acid level and cellular signaling, such as ERK
phosphorylation, activated by ischemic PostC. Since dys-
lipidemia was also shown to attenuate the infarct size-
limiting effect of ischemic PC [60,61], restoration of
myocardial response to PostC in the diabetic heart by
islet cell transplantation might be achieved by
normalization of both plasma glucose level and lipid
profile. Nevertheless, circumstantial evidence in animal
experiments supports the notion that normalization of
the metabolic profile restores protective signaling
mechanisms in the DM heart.
Clinical studies on PC
PC protection in human hearts has been demonstrated
by results of in vitro experiments using human ventricu-
lar myocytes [62] and atrial trabeculae [63] and by
detailed analyses of myocardial responses in patients
with naturally occurring ischemic syndromes [64,65].
Since ischemic PC and PC-like phenomena in human
hearts have been recently reviewed elsewhere [7,65], we
briefly summarize the results that are relevant to the
effects of DM on ischemic PC. As for PC-like effects of
preinfarct angina, different groups reported that pre-
Table 3 Effect of diabetes mellitus on cardioprotection by pre- and post-conditioning






Rat (SD) 1 4 w 3x 5I5R Shi-Ting Biomed Pharmacother 2010
Rat (Wistar) 2 11-12 m 3x 5I5R Liu Circulation 1993
Rat (Wistar) 1 6 w LiCl 20 mM, IND 1 μM, SB 3 μM Yadav Mol Cell Biochem 2010
Rat (Zucker diabetic fatty) 2 (10-12 w old) Rosiglitazone 3 mg/kg for 1 week Yue Diabetes 2005
Rat (OLETF) 2 (25-30 w old) SB 1.2 mg/kg Miki Diabetes 2009
Rat (Goto-Kakizaki) 2 3x 5I10R Tsang Diabetes 2005
Rat (Goto-Kakizaki) 2 (12 w old) WY 1 mg/kg Bulhak Am J Physiol 2009
Rat (Goto-Kakizaki) 2 olprinone 10 μg/kg Matsumoto Cardiovasc Drug Ther 2009
Mice (ob/ob) 2 (8-10 w old) Metformin 125 μg/kg Calvert Diabetes 2008
Mice (KK-Ay) 2 (6 w old) Pioglitazone 25 mg/kg for 2 week Honda J Mol Cell Cardiol 2008
PostC
Rat (SD) 1 2 w SB 0.6 mg/kg Gross Diabetes 2007
Rat (Wistar) 1 4 w SB 3 μM Ghaboura Basic Res Cardiol 2011
Rat (OLETF) 2 (25-30 w old) BIO 0.08 mg/kg Hotta Circ Res 2010
Rat (Goto-Kakizaki) 2 Metformin 50 μM Bhamra Basic Res Cardiol 2008
Mice (ob/ob) 2 (8-10 w old) Metformin 125 μg/kg Calvert Diabetes 2008
Impaired protection
PC
Dog 1 3 w 4x 5I5R Kersten Am J Physiol 2000
Dog 1 3 w Diazoxide 2.5 mg/kg Kersten Am J Physiol 2001
Rabbit (NZ) 1 4-5 w 3x 2I2R Nieszner Exp Clin Endocrinol Diabetes 2002
Rat (SD) 1 8 w 3x 5I5R Wang Biomedicine Aging Pathol 2011
Rat (Wistar) 1 6 w 5I5R Galagudza Neurosci Behav Physiol 2007
Rat (Wistar) 1 6 w 4x 5I5R Yadav Mol Cell Biochem 2010
Rat (Wistar) 2 10-12 w Metformin 200 mg/kg for 3 days Kravchuk Exp Diabetes Res 2011
Rat (Zucker obese) 2 (10-12 w old) 5I5R, Diazoxide 10 mg/kg Katakam Am J Physiol 2007
Rat (Zucker diabetic fatty) 2 (16 w old) 4x 2I3R Kristiansen Diabetologia 2004
Rat (OLETF) 2 (25-30 w old) EPO 5000 U/kg Miki Diabetes 2009
Rat (OLETF) 2 (25-30 w old) EPO 5000 U/kg, DADLE 1 mg/kg Hotta Circ Res 2010
Rat (Goto-Kakizaki) 2 (16 w old) 4x 2I3R Kristiansen Diabetologia 2004
Rat (Goto-Kakizaki) 2 5I10R, 2x 5I10R Tsang Diabetes 2005
Rat (Goto-Kakizaki) 2 (16-18 w old) EPO 5000 U/kg Miki Diabetes 2009
Rat (Goto-Kakizaki) 2 isoflurane 1.0% Matsumoto Cardiovasc Drug Ther 2009
PostC
Rat (SD) 1 2 w Morphine 0.3 mg/kg Gross Diabetes 2007
Rat (SD) 1 4-5 w 3x 20sR20sI, sevoflurane 1.0 MAC Drenger Anesthesiology 2011
Rat (Wistar) 1 4 w Darbopoetin alpha 5 μg/kg Ghaboura Basic Res Cardiol 2011
Mice 1 2 w 3x 10sR10sI, 6x 10sR10sI Przyklenk Antioxid Redox Signal 2011
Mice (ob/ob) 2 (8-10 w old) 6x 10sR10sI Bouhidel Am J Physiol 2008
Mice (ob/ob) 2 (12-14 w old) 3x 10sR10sI, 6x 10sR10sI Przyklenk Antioxid Redox Signal 2011
Mice (ob/ob) 2 (10-12 w old) 6x 10sR10sI Zhu J Cell Mol Med 2011
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Table 3 Effect of diabetes mellitus on cardioprotection by pre- and post-conditioning (Continued)
Mice (KK-Ay) 2 (6 w old) Pioglitazone 25 mg/kg Honda J Mol Cell Cardiol 2008
Late PC
Rabbit (NZ white) 1 5-6 w 5I24hR Ebel Pflugers Arch 2003
IND indirubin-3 monooxime (a GSK-3β inhibitor), SB SB216763 (a GSK-3β inhibitor), WY 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (a PPAR-α agonist), BIO
6-bromo-indirubin-3'-oxime (a GSK3β inhibitor), EPO erythropoietin, DADLE [D-Ala2, D-Leu5]-enkephalin acetate (a δ-opioid receptor agonist), 5I5R 5-min ischemia/
5-min reperfusion, 5I24hR 5-min ischemia/24-hour reperfusion, 10sR10sI 10-second reperfusion/10-second ischemia, MAC minimal alveolar concentration, w weeks,
m months.
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determined by creatine kinase (CK) release, improved
left ventricular function and reduced mortality [64,66].
Furthermore, in overall analysis of AMI patients, angina
before AMI was associated with better long-term prog-
nosis [67,68]. However, in patients with DM, beneficial
effects of pre-infarct angina were not detected [69]. Ishi-
hara et al. [69] showed that CK release and recovery of
cardiac function and in-hospital mortality after AMI
were similar in DM patients with and without pre-Table 4 Effect of hyperglycemia on cardioprotection by pre- a





Dog before I 397 Diazoxide 5.0 mg
Dog before I 291 Isoflurane 1.0 MA
Rat (SD) before and during I 360 Fasudil 0.5 mg/kg
Rat (Wistar) before and during I 446 Sevoflurane 1.0 M
Rat (Wistar) before and during I 343, 447 MIL 30 μg/kg, LE
Impaired protection
PC
Dog before I 296 4x 5I5R
Dog before I 329 Diazoxide 2.5 mg
Dog before I 581, 558 Isoflurane 0.5, 1.0
Dog before I 293 4x 5I5R
Rabbit (NZ white) before I 281 Isoflurane 1.0 MA
Rat (Wistar) before I or during I >400 Desflurane 1.0 M
PostC
Rabbit (NZ white) before and during I 353 Isoflurane 1.0 MA
Rat (SD) before and during I 360 Diazoxide 10 mg




Rat (WOKW) (28 w old) 105 3x 30sI30sR
NZ New Zealand, SD Sprague–Dawley, WOKW Wistar-Ottawa-Karlsburg W, before I b
CysA cyclosporine A, MIL milrinone, LEVO levosimendan, 5I5R 5-min ischemia/5-mininfarct angina. DM-induced impairment of ischemic PC
protection in human hearts has also been indicated by
studies in which myocardial injury was assessed during
angioplasty [70] and during a treadmill exercise test [71]
by use of electrocardiography.
Direct evidence for diabetes-induced loss of ischemic
PC protection in the human myocardium was provided
by an in vitro experiment using atrial trabeculae
obtained at open heart surgery. CK release and contract-




/kg Kersten Am J Physiol 2001
C Kehl Anesthesiology 2002
Ichinomiya Cardiovasc Diabetol 2012
AC+CysA 5 mg/kg Huhn Br J Anaesth 2008
VO 100 μg/kg Matsumoto Cardiovasc Diabetol 2012
Kersten Am J Physiol 1998
/kg Kersten Am J Physiol 2001
MAC Kehl Anesthesiology 2002
Gu Anesthesiology 2008
C Amour Anesthesiology 2010
AC Weber Eur J Pharmacol 2008
C Raphael J Cardiovasc Pharmacol 2010
/kg, Fasudil 0.15 mg/kg Ichinomiya Cardiovasc Diabetol 2012
AC, CysA 5 mg/kg Huhn Br J Anaesth 2008
Wagner J Cardiovasc Pharmacol 2008
efore ischemia, during I during ischemia, MAC minimal alveolar concentration,
reperfusion, 30sR30sI 30-second reperfusion/30-second ischemia.






ST resolution LV function Enzyme release Infarct size
Ischemic PostC
Staat 20 vs. 13 58 vs. 56 4x 60sR/I Improved N/A Reduced (peak, AUC) N/A
Laskey N/A 58 vs. 58 2x 90sR/I Improved N/A Nochange (peak) N/A
Ma 38 vs. 45 64 vs. 64 3x 30sR/I N/A Improved WMSI Reduced (peak) N/A
Yang 26 vs. 28 59 vs. 63 3x 30sR/I No change No change Reduced (AUC) Reduced (SPECT, 1w)
Thibault 12 vs. 10 56 vs. 56 4x 60sR/I N/A Improved EF, WMSI Reduced (AUC) Reduced (SPECT, 6m)
Laskey 38 vs. 42 60 vs. 58 2x 90sR/I Improved No change Reduced (peak) N/A
Xue 21 vs. 29 54 vs. 62 4x 60sR/I Improved Improved EF, WMSI Reduced (peak, AUC) Reduced (SPECT, 1w)
Lønborg 7 vs. 7 61 vs. 62 4x 30sR/I No change No change N/A Reduced (CMR, 3m)
Sörensson 25 vs. 17 63 vs. 62 4x 60sR/I N/A No change *1 No change (AUC) No change (CMR, 1w) *1
Freixa 23 vs. 17 59 vs. 60 4x 60sR/I N/A No change No change (peak) No change (CMR, 1w & 6m)
Tarantini 18 vs. 3 60 vs. 60 4x 60sR/I No change No change No change (AUC) No change (CMR, 1m)
DM diabetes mellitus, MBG myocardial blush grade, CF coronary flow, WMSI wall motion score index, EF ejection fraction, AUC area under the curve, MACE major
adverse cardiac events, SPECT single photon emission computed tomography, CMR cardiovascular magnetic resonance, w week, m month;
*1 Improved by postconditioning with large area at risk.
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diabetic patients but not in trabeculae from diabetic
patients [63,72].
Clinical studies on PostC
In contrast to PC, PostC or administration of its mi-
metic at the time of reperfusion is clinically feasible. In
2005, Staat et al. [73] translated for the first time the
concept of ischemic PostC into the clinical setting.
PostC with four cycles of 1-min inflation and 1-min de-
flation before full reperfusion successfully reduced CK
release in a small and selected cohort of patients with
AMI. Efficacy of ischemic PostC in patients with AMI
was subsequently confirmed in a number of small-scale
studies, using as endpoints cardiac biomarkers, ECG ST-
segment resolution, and anatomic infarct size (Table 5).
However, three recent studies failed to show protection
by ischemic PostC in terms of CK and troponin release,
LV function or infarct size that was determined by
delayed enhancement magnetic resonance imaging
(MRI) [74-76]. The reasons for the discrepant results re-
main uncertain, but there are some possibilities: differ-
ences in the protocols of ischemic PostC, presence of
co-morbidities and use of different pharmacological
agents for the co-morbidities.
In the PostC protocol, duration from reperfusion to
the first re-occlusion and number of re-occlusions have
been shown to influence the infarct size-limiting effects
of PostC in animal models of AMI [77-79]. Retrospect-
ive analyses by Darling et al. [80] and Wang et al. [81]
suggest that larger numbers of balloon inflations–
deflations were associated with greater protection in
patients with AMI. However, an appropriate algorithmof PostC stimulus to maximally protect the human
myocardium has not been established. In addition, pro-
tection by PostC in animal models of AMI is attenu-
ated with aging and presence of co-morbidities, such
as DM, hypertension and hypercholesterolemia [6,11].
Although characteristics of patients, such as age and
prevalence of DM, seem to be similar in the human
studies (Table 5), difference in durations of the co-
morbidities might have been involved in the different
outcomes. Nevertheless, the effect of DM on protection
afforded by PostC has not been specifically examined
in clinical studies.
The effects of pharmacological PostC (i.e., adminis-
tration of pharmacological agents at reperfusion) on
myocardial injury have been examined in a number of
clinical trials. Results of the trials are a mixture of
positive and negative results, and the reason for the
discrepancy remains unknown [82-92]. Adenosine infu-
sion limited infarct size, but neither the death rate
during 6-month follow-up nor the rate of re-
hospitalization for heart failure were reduced by the
adenosine treatment [82,84]. A post hoc analysis sug-
gested that only patients with early reperfusion therapy
received clinical benefits of adenosine, such as a reduc-
tion in death or heart failure [85]. In the J-WIND trial
[86], the effects of nicorandil and ANP on infarct size
in different study arms were examined. Administration
of nicorandil failed to significantly limit infarct size,
though recombinant ANP infusion was shown to in-
duce a small but significant reduction in infarct size.
The results of studies on the effect of erythropoietin
administered at reperfusion were discrepant [87-92].
Taken together, there are a few promising agent for
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their effects has been unequivocally demonstrated to
be sufficient for improving prognosis.
Effects of anti-diabetic medications on AMI in
diabetic patients
Possible adverse effects of sulfonylureas on cardiac
events in DM patients have been debated for decades,
and recent studies have indicated that cardiovascular
risk was significantly higher in DM patients treated with
sulfonylureas than in those who received metformin
monotherapy [93,94]. Sulphonylureas have been shown
to inhibit protection of PC and PostC by blocking the
ATP-sensitive K+ channel (KATP channel) in cardiomyo-
cytes, raising concern that such actions of sulphonylur-
eas may be detrimental at the time of AMI in DM
patients. However, the effects on PC and PostC are actu-
ally not uniform across sulfonylureas. Glibenclamide, a
non-specific blocker of the KATP channel, abrogated the
infarct size-limiting effect of PC and PostC in non-
diabetic animals [6,7,95]. In contrast, glimepiride, a
second-generation sulfonylurea, did not block the pro-
tective effect of PC in the animal myocardium or human
myocardium [96,97], presumably because this agent has
few cardiac actions [98]. In addition, glimepiride was
shown to have a PostC-mimetic action by activation of
PI3K/Akt in the rabbit myocardium [99]. However, the
effects of sulfonylureas on PC in diabetes have been
tested in only a few studies [51,96], since PC and PostC
failed to limit infarction in most of the DM models.
Interestingly, Nieszner et al. [51] reported that infarct-
sparing effect of PC in alloxan-treated diabetic rabbits
was restored by pretreatment with a low dose, but not a
high dose, of glibenclamide. The mechanism by which
glibenclamide restored myocardial response to PC in the
DM rabbit is unclear. However, beneficial effects of gly-
cemic control, possibly on PI3K/Akt signaling, might
have overwhelmed the effect of partial inhibition of car-
diac KATP channels when an appropriate dose of gliben-
clamide was selected.
Metformin is an insulin-sensitizing agent that reduces
hepatic glucose output and increases the uptake of glu-
cose in peripheral tissues, including the skeletal muscle.
In non-diabetic animals, metformin reduced infarct size
by activation of AMP-activated protein kinase and/or
Akt [95]. However, whether metformin is additive to is-
chemic PC or PostC has not been examined. Infarct
size-limiting effect of metformin in diabetic animals was
controversial: there are two positive reports [40,100] and
one negative report [101].
Thiazolidinediones (pioglitazone, rosiglitazone) admi-
nistered before ischemia reduced infarct size in both nor-
mal and diabetic animals [39,41,95]. However, the impact
of the cardioprotective effect of thiazolidinediones onclinical outcome is unclear, since the effects of pioglita-
zone and rosiglitazone on risk of cardiovascular events
appear discrepant [102].
In the past few years, growing evidence has demon-
strated cardiovascular effects of incretin-based therapy
using glucagon-like peptide-1 (GLP-1) receptor agonists
and inhibitors of dipeptidyl peptidase-4 (DPP-4) [95,103-
105]. However, the effects of GLP-1 receptor agonists or
DPP-4 inhibitors on ischemia/reperfusion injury have
not been examined in diabetic animals except for a study
by Huisamen et al. [106] They reported that enlargement
of infarct size in obese pre-diabetic rats was reduced by
treatment with a DPP-4 inhibitor for 4 weeks [106]. Fur-
ther investigation is necessary for clarifying the effects of
GLP-1 analogues and DPP-4 inhibitors on intracellular
protective signaling and its modification by DM, though
there are a number of on-going large-scale clinical trials
to test the effects of incretin-based therapy on cardiovas-
cular outcomes [107].
Conclusions and perspectives
DM potentially increases myocardial susceptibility to is-
chemia/reperfusion injury, though it cannot be explained
by chronic hyperglycemia alone. DM also modifies myo-
cardial responses to ischemic and pharmacological PC
and PostC by disruption of intracellular signaling re-
sponsible for enhancement of resistance to cell death.
These alterations in the diabetic heart appear to underlie
the poor prognosis of DM patients after AMI. In
addition, a defect of the protective mechanisms caused
by aging, DM and possibly other co-morbidities is one
of possible reasons why infarct size-limiting effects of
agents in animal studies could not have been translated
into AMI patients.
Analyses of modifications of cytoprotective signaling
by DM, heart failure, dyslipidemia and hypertension gen-
erally showed that defects in the signaling by the patho-
logical factors are upstream of a step of GSK-3β
phosphorylation and mPTP regulation [6,9]. Hence, a
reasonable approach to protect the heart in DM patients
is manipulation of protective mechanisms at the level of
GSK-3β or mPTP. Blockade of mPTP opening by cyclo-
sporine A at the time of reperfusion is one such ap-
proach, and its effect was first examined in 58 AMI
patients [108]. Infarct size determined by MRI at 5 days
after AMI was significantly limited by cyclosporine A
and the beneficial effects persisted until 6 month after
AMI [109]. The results are very promising and support
the feasibility of a strategy for cardioprotection targeting
the mPTP. However, how DM modifies the mPTP regu-
lation and how we can suppress opening of the mPTP at
the time of reperfusion need to be further investigated
for devising a novel therapy for cardioprotection in DM
patients.
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